CorMedix Inc. (CRMD)
Largest Insider Buys in Sector
CRMD Stock Price History Chart
CRMD Stock Performance
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as …
Insider Activity of CorMedix Inc.
Over the last 12 months, insiders at CorMedix Inc. have bought $65,703 and sold $1.57M worth of CorMedix Inc. stock.
On average, over the past 5 years, insiders at CorMedix Inc. have bought $238,573 and sold $810,532 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Todisco Joseph (Chief Executive Officer) — $101,436. Mistry Erin (EVP, Chief Commercial Officer) — $14,985.
The last purchase of 1,500 shares for transaction amount of $14,985 was made by Mistry Erin (EVP, Chief Commercial Officer) on 2024‑10‑31.
List of Insider Buy and Sell Transactions, CorMedix Inc.
| 2024-11-14 | Sale | EVP | 140,027 0.2312% | $11.18 | $1.57M | 0.00% | ||
| 2024-10-31 | EVP, Chief Commercial Officer | 1,500 0.0026% | $9.99 | $14,985 | -1.99% | |||
| 2024-03-13 | Chief Executive Officer | 13,561 0.024% | $3.74 | $50,718 | +38.36% | |||
| 2023-12-15 | director | 3,000 0.0055% | $3.30 | $9,900 | +53.78% | |||
| 2023-12-14 | director | 3,000 0.0055% | $3.45 | $10,350 | +47.39% | |||
| 2023-11-17 | Chief Commercial Officer | 1,000 0.0018% | $4.00 | $4,000 | +15.82% | |||
| 2023-09-08 | Chief Executive Officer | 10,000 0.0183% | $3.71 | $37,100 | +1.76% | |||
| 2023-05-18 | director | 6,000 0.0139% | $4.54 | $27,258 | -14.19% | |||
| 2023-05-17 | Chief Executive Officer | 5,000 0.0119% | $4.58 | $22,900 | -13.01% | |||
| 2023-05-17 | director | 10,000 0.0227% | $4.37 | $43,735 | -13.01% | |||
| 2023-05-17 | director | 10,000 0.0241% | $4.65 | $46,500 | -13.01% | |||
| 2023-05-17 | director | 3,000 0.0067% | $4.33 | $12,980 | -13.01% | |||
| 2022-11-15 | Chief Executive Officer | 20,000 0.0514% | $3.82 | $76,400 | +11.79% | |||
| 2022-08-24 | Chief Executive Officer | 4,700 0.0114% | $3.92 | $18,424 | +4.58% | |||
| 2022-05-17 | 5,000 0.0124% | $3.78 | $18,900 | +3.40% | ||||
| 2022-05-16 | Chief Executive Officer | 10,000 0.0235% | $3.38 | $33,800 | +8.86% | |||
| 2021-12-06 | Interim CEO and CFO | 2,000 0.0052% | $4.50 | $9,000 | -13.93% | |||
| 2021-11-17 | Interim CEO and CFO | 1,000 0.0027% | $5.07 | $5,070 | -20.71% | |||
| 2021-11-16 | director | 10,000 0.0262% | $5.14 | $51,400 | -22.60% | |||
| 2021-05-21 | Sale | EVP, Head of Clinical Ops | 8,000 0.0212% | $6.92 | $55,394 | -28.17% |
Insider Historical Profitability
| Todisco Joseph | Chief Executive Officer | 352839 0.5815% | $8.45 | 6 | 0 | +1.12% |
| Mistry Erin | EVP, Chief Commercial Officer | 52011 0.0857% | $8.45 | 2 | 0 | |
| Gelbfish Gary A. | director | 2101121 3.4628% | $8.45 | 2 | 0 | <0.0001% |
| TELLEZ CORA M | director | 182371 0.3006% | $8.45 | 15 | 0 | <0.0001% |
| Khan Mehmood | director | 178767 0.2946% | $8.45 | 10 | 0 | +14.8% |
Institutional Investor Ownership
| BlackRock | $14.78M | 6.35 | 3.49M | -0.59% | -$87,772.24 | <0.0001 | |
| Nomura Holdings | $12.51M | 5.37 | 2.95M | +0.17% | +$20,720.88 | 0.11 | |
| The Vanguard Group | $12.42M | 5.33 | 2.93M | +3.64% | +$436,088.25 | <0.0001 | |
| Elliott Investment Management L P | $6.57M | 2.82 | 1.55M | 0% | +$0 | 0.07 | |
| Geode Capital Management | $5.02M | 2.15 | 1.18M | +2.1% | +$103,315.71 | <0.0001 |